Researchers are exploring the use of targeted protein degradation, including proteolysis-targeting chimeras (PROTACs), as a potential treatment for acute myeloid leukemia and other hematologic malignancies. This approach involves targeting specific proteins for degradation, with some studies focusing on the use of degrader-antibody conjugates and others examining the role of certain proteins, such as cereblon, in leukemia therapies. The development of these treatments is an active area of research, with various studies and preclinical data being presented on their potential efficacy and tolerability.